Brief: Transgene And NEC Start Two Clinical Trials With TG4050

Transgene SA

07/01/2020 06:39

Jan 7 (Reuters) - Transgene SA  TRNG.PA :
    * TRANSGENE AND NEC START TWO CLINICAL TRIALS WITH TG4050,
AN
INDIVIDUALIZED AI-POWERED CANCER VACCINE FOR OVARIAN AND HEAD &
NECK CANCERS
    * FIRST PATIENTS ENROLLED IN TWO PHASE 1 TRIALS AT THE MAYO
CLINIC
AND TOULOUSE ONCOPOLE
    * TG4050 MOVES THERAPEUTIC VACCINATION INTO DIGITAL AGE:
COMBINES
TRANSGENE'S EXPERTISE IN VIRAL VECTORS WITH NEC'S CUTTING-EDGE
ARTIFICIAL INTELLIGENCE (AI) CAPABILITIES
    * OVEL IMMUNOTHERAPY IS FULLY TAILORED TO EACH INDIVIDUAL BY
GENERATING AN IMMUNE RESPONSE THAT TARGETS HIGHLY SPECIFIC
PATIENT TUMOR MUTATIONS

Source text for Eikon:  ID:nBw9xhNDna 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))